Blueberry Therapeutics Completes £10M Series B Funding
Summary
The company intends to use the funds for its development program for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne and atopic dermatitis programmes.In conjunction with the funding, Dr. Huaizheng Peng, General Manager of International Operations at CMS and Chief Executive Officer of A&B, joined Blueberry’s board.Led by Dr. John Ridden, Chief Executive Officer, Blueberry Therapeutics focuses on developing innovative nanomedicines for difficult to treat skin and nail infections.The company is using its nano-formulation technology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.Blueberry combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market.